SP-MHCI-0650-3

Human RSV A (strain A2) Fusion glycoprotein F0 201-215, KQLLPIVNKQSCSIS

US$507.00

In stock

Description

About Human RSV A (strain A2) Fusion glycoprotein F0 201-215, KQLLPIVNKQSCSIS

The Respiratory Syncytial Virus (RSV) A (strain A2) Fusion glycoprotein F0 Peptide (IEDB: 99398) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Fusion glycoprotein F0 Peptide, H-KQLLPIVNKQSCSIS-OH (Uniprot: P03420 aa: 201-215) from JPT is produced under strict quality control and quality management.

Human RSV A (strain A2) Fusion glycoprotein F0 201-215, KQLLPIVNKQSCSIS - Specifications

  • Peptide sequence: H-KQLLPIVNKQSCSIS-OH
  • Amount: 10 mg (10 x 1 mg)
  • Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
  • Counterion: TFA
  • Delivery Format: Freeze-dried in glass vial
  • Application(s): T-cell Immunity
  • Condition(s)/Topic(s): Infection
  • Standard Delivery Time: approx. 3 weeks

JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!

Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for Human RSV A (strain A2) Fusion glycoprotein F0 201-215, KQLLPIVNKQSCSIS

References:
Read References with JPT’s Antigen Peptides
Human RSV A (strain A2) Fusion glycoprotein F0 201-215, KQLLPIVNKQSCSIS has been described in:
Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes., J Virol, 1991 (PMID: 1710289)
Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection., J Clin Invest, 2020 (PMID: 31815739)
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade., Front Immunol, 2022 (PMID: 35874702)

Documentation

Documentation for Human RSV A (strain A2) Fusion glycoprotein F0 201-215, KQLLPIVNKQSCSIS

Properties

Properties of Human RSV A (strain A2) Fusion glycoprotein F0 201-215, KQLLPIVNKQSCSIS

Properties Values
Application: T-cell immunity
Category: Antigen Peptides
Condition / Topic: Infection
Layout: Freeze-dried in glass vial
Organism: Respiratory Syncytial Virus (RSV)
Protein Name: Fusion glycoprotein F0
Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
Quantification: No, Yes

Further Information to Human RSV A (strain A2) Fusion glycoprotein F0 201-215, KQLLPIVNKQSCSIS

Information Values
Sequence: H-KQLLPIVNKQSCSIS-OH
Specifications: 15mer peptide as TFA salt
Loading...

Check our list of products, click and go.

Get a quote